FDA Aims To Clear Hurdles For Severe Bleeding Products With Workshop, Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Community consent and other controversial practices involved with enrolling trauma patients in clinical trials will be addressed.